

---

## Product Data Sheet

---

Product Name: GW841819X

Cat. No.: GC16611

### Chemical Properties

Cas. No.

Chemical Name (R)-benzyl (6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)carbamate

SMILES C1C(C=C1)=CC=C1C2=N[C@@H](NC(OCC3=CC=CC=C3)=O)C4=NN=C(C)N4C5=CC=C(OC)C=C52Formula  $C_{26}H_{22}ClN_5O_3$  M.Wt 487.94Solubility Soluble in DMSO Storage Store at  $-20^{\circ}C$ General tips For obtaining a higher solubility, please warm the tube at  $37^{\circ}C$  and shake it in the ultrasonic bath for a while. Stock solution can be stored below  $-20^{\circ}C$  for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure 

### Background

GW841819X is an analogue of (+)-JQ1 and a novel inhibitor of BET bromodomains. GW841819X was a single enantiomer but of undefined chirality at the 4-position of the benzodiazepine ring<sup>3</sup>.

GW841819X and JQ1 were recently discovered that bind to the acetyl-lysine binding pocket of BET bromodomains with  $K_d$  ranges from 50 to 370 nM [1]. GW841819X bounded to both the individual BD1 and BD2 domains with affinities of 46 and 52.5 nM, respectively. GW841819X-Brd3 interaction was estimated to be around 70 nM<sup>4</sup>.

GW841819X displayed activity in vivo against NUT-midline carcinoma, multiple myeloma, mixed-lineage leukemia, and acute myeloid leukemia<sup>1</sup>. It also potent induced the ApoA1 reporter gene with an  $EC_{50}$  of 440 nM. It had very little effect on LDL-R luciferase activity at the concentrations at which it induces ApoA1 expression,

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

suggesting that the effect is indeed specific <sup>3</sup>. GW841819X competed directly with GATA1 site for BD1 binding and also specifically blocked the interaction between Brd3 and acetylated GATA1 <sup>4</sup>. Recent findings reported that GW841819X are chose as an interest compound to further develop into potential drugs against diseases including cancer, HIV infection and heart disease <sup>2</sup>.

### References:

1. Baud MG, Lin-Shiao E, Cardote T et al. Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. Science. 2014 Oct 31;346(6209):638-41.
2. Floyd SR, Pacold ME, Huang Q et al. The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature. 2013 Jun 13;498(7453):246-50.
3. Chung CW, Coste H, White JH et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011 Jun 9;54(11):3827-38.
4. Gamsjaeger R, Webb SR, Lamonica JM et al. Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3. Mol Cell Biol. 2011 Jul;31(13):2632-40.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA